THE DOSE

your daily dose of Innovative, trending, and groundbreaking stories from across the cosmos.


SykoActive SykoActive

Revolutionary Gene Therapy Breakthrough Offers Hope for Rare Genetic Disorders

Researchers have achieved a significant breakthrough in the field of gene therapy, demonstrating substantial potential in treating rare genetic disorders. Utilizing the innovative CRISPR-Cas9 gene editing technology, scientists can now target and correct specific genetic mutations that cause these disorders. Unlike conventional gene therapy, which introduces modified genes into the body, this targeted approach directly corrects faulty genes at their source. This advancement could potentially offer a permanent cure for these conditions and paves the way for future gene-based treatments.

Read More
SykoActive SykoActive

Michigan Legislation Seeks to Improve Foster Youth Education

Michigan lawmakers are taking steps to address the education crisis among foster youth. Three bills have been introduced to improve high school graduation rates and to ensure that the credits earned by these students in residential facilities count towards their graduation.

Read More
SykoActive SykoActive

The Hottest Google Cloud and Workspace Tools of 2023

Google Cloud has revolutionized its portfolio with a series of groundbreaking tools. Among the top 10 hottest tools, Duet AI for Google Workspace stands out, providing enhanced collaboration features powered by artificial intelligence. Another notable tool is the Generative AI App Builder, empowering users to create dynamic and personalized applications using generative AI technology.

Read More
SykoActive SykoActive

Osmind Research Activities: Advancing Mental Health Interventions

Osmind, a leading organization in mental health research, is making significant strides in advancing mental health interventions. Through their research activities, they aim to establish the safety and efficacy of ketamine therapy and psychedelic integration,

The research activities carried out by Osmind hold great significance in the field of mental health interventions. By providing evidence-based insights into the safety and efficacy of ketamine therapy and psychedelic integration, Osmind's research could contribute to the establishment of new standards for mental health treatments. Moreover, their findings have the potential to influence policy decisions and insurance coverage, making these innovative therapies more accessible to individuals in need.

Read More
SykoActive SykoActive

Psychedelics and Amnesia: An Innovative Approach to Research from the University of Wisconsin

Innovative exploration of the medicinal potential of psychedelics, researchers at the Transdisciplinary Center for Research in Psychoactive Substances at the University of Wisconsin-Madison have launched a pioneering study.The groundbreaking technique, dubbed the "active placebo" strategy, involves inducing a mild hallucinatory state in all participants, including those in the placebo group, using a naturally occurring substance.

Read More
SykoActive SykoActive

Blockchain Technology: A Promising Safeguard Against Rogue AI

Coinbase's head of research, David Duong, suggests that blockchain technology could serve as a safeguard against uncontrolled AI. The report suggests potential areas of collaboration between blockchain and AI, with blockchain potentially helping to combat misinformation and shed light on AI decision-making.

Read More
SykoActive SykoActive

Nevada Senate Approves Establishment of Psychedelics Research Group

The Nevada Senate has passed a bill to form a research group tasked with examining the therapeutic potential of regulated psychedelic use. This initiative underscores the growing understanding of the potential mental health benefits these substances may provide when used in a controlled, therapeutic context.

Read More
SykoActive SykoActive

Colorado Legalizes and Regulates Psychedelics

The Governor of Colorado has approved a landmark bill, SB23-290, to regulate the use of psychedelics in the state. This bill removes legal restrictions on owning psychedelic substances such as DMT, mescaline, ibogaine, psilocybin, or psilocin for personal use.

Read More
SykoActive SykoActive

Beat Plastic: Global Momentum Grows for a Treaty on Plastic Pollution

World Environment Day is the biggest international day for the environment. Led by the United Nations Environment Programme (UNEP), and held annually since 1973, it has grown to be the largest global platform for environmental outreach. It is celebrated by millions of people across the world.

World Environment Day 2023 is hosted by Côte d'Ivoire and supported by the Netherlands and the theme will focus on solutions to plastic pollution under the campaign #BeatPlasticPollution. It is a reminder that people’s actions on plastic pollution matters. The steps governments and businesses are taking to tackle plastic pollution are the consequence of this action.

Join millions around the world to #BeatPlasticPollution.

Read More
SykoActive SykoActive

Ketamine Shows Promise as a Treatment for Various Mental Health Conditions

A recent study conducted by researchers from the University of British Columbia Okanagan and the University of Exeter has shed light on the potential of ketamine in treating a range of mental health disorders, including depression, PTSD, bipolar disorder, and eating disorders. By analyzing over 150 global studies on sub-anesthetic doses of ketamine, the researchers discovered significant anti-depressant and anti-suicidal properties. This breakthrough could pave the way for innovative and more effective mental health treatments.

Read More
SykoActive SykoActive

Elon Musk's Neuralink Secures FDA Approval for Human Brain Implant Study

Neuralink, the brain-implant company founded by visionary entrepreneur Elon Musk, has reached a significant milestone with the approval of its first-in-human clinical trial by the U.S. Food and Drug Administration (FDA). This breakthrough represents a crucial step forward for Neuralink, following previous challenges in obtaining regulatory clearance for its groundbreaking technology. With the FDA's green light, Neuralink is now one step closer to fulfilling its mission of utilizing brain implants to address a wide range of conditions and potentially unlock extraordinary capabilities such as web browsing and telepathy.

Read More
SykoActive SykoActive

The Oregon Psychedelic Industry Begins

With The regulatory framework of measure 109 now in place, the start of 2023 means that Oregon is beginning to accept applications for licenses to operate in the new psychedelic industry.

Read More
SykoActive SykoActive

Psychedelic Therapies Included In Your Employee Benefits

Enthea, a provider of psychedelic healthcare insurance plans, declared that it will expand its services into 40 markets across the US in 2023 with the goal of making workplace benefits for psychedelic-assisted therapies reasonable, equitable, and available.

Read More
SykoActive SykoActive

Colorado Becomes 2nd State To Decriminalize Psychedelics

Colorado Votes on Decriminalizing the Possession, Storing, Using, Processing, Transporting, Purchasing, Obtaining, or INGESTING NATURAL MEDICINE FOR PERSONAL USE AND EVEN GIVING AWAY NATURAL MEDICINE FOR PERSONAL USE WITHOUT REMUNERATION TO A PERSON OR PERSONS TWENTY-ONE YEARS OF AGE OR OLDER!

Read More
SykoActive SykoActive

Democrats Work With Republicans To Give Patients Access To Psychedelics

Democratic senator, Cory Booker, and Republican Rand Paul collaborated on a new version of the “Right to Try” bill called the “Right To Try Clarification Act”. The Right to Try Clarification Act is a proposed law that would clarify the right of terminally ill patients to access experimental therapies, such as psychedelic-assisted therapy. This right is currently protected by a federal statute called the “Right to Try Act.”

Read More
SykoActive SykoActive

San Francisco Will Vote On Decriminalizing Psychedelics Next Year

Senator Scott Wiener’s Senate Bill 519, which decriminalizes the possession and personal use of certain psychedelic drugs will be voted on next year. San Francisco Supervisors Dean Preston and Hillary Ronen introduced legislation that would decriminalize use and possession of psilocybin mushrooms, LSD, MDMA, DMT, and Mescaline.

Read More